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Abstract  
The post-translational modification of proteins by O-linked N-acetylglucosamine (O-GlcNAc) 
dynamically programs cellular physiology to maintain homeostasis and tailor biochemical 
pathways to meet context-dependant cellular needs. Despite diverse roles for O-GlcNAc, only two 
enzymes act antagonistically to govern its cycling; O-GlcNAc transferase (OGT) installs the 
monosaccharide on target proteins and O-GlcNAc hydrolase (OGA) removes it. Recent literature 
has exposed a network of mechanisms regulating these two enzymes to choreograph global, and 
target-specific, O-GlcNAc cycling in response to cellular stress and nutrient availability. Herein, we 
amalgamate these emerging mechanisms from a structural and molecular perspective to explore 
how the cell exerts fine control to regulate O-GlcNAcylation of diverse proteins in a selective 
fashion. 
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Introduction  
TｴW Iﾗ┗;ﾉWﾐデ ;デデ;IｴﾏWﾐデ ﾗa é-linked N-acetylglucosamine to the hydroxyl group of 
protein serine and threonine residues has been identified on hundreds of nucleocytosolic and 
mitochondrial proteins, and is abundant throughout all multicellular eukaryotes [1]. The donor 
substrate for OGT catalyzed O-GlcNAcylation is uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc), the biosynthetic product of the nutrient responsive hexosamine biosynthetic pathway 
(HBSP). Protein O-GlcNAc levels are thus tied to nutrient status through HBSP flux, facilitated by 
the reversible nature of O-GlcNAc that can be installed and removed multiple times during the 
lifespan of a protein [1]. O-GlcNAc is being found to modulate proteins in an increasing variety of 
ways including manipulation of: protein function, protein-protein interactions, protein 
localization, and protein stability (reviewed in [1]). Additionally, O-GlcNAc has the potential to 
compete directly and indirectly with phosphorylation sites and may agonize or antagonize other 
post-translational modifications (PTMs), including ubiquitinylation, sumoylation, and acetylation 
(reviewed in [1]), although relatively few such interactions have been demonstrated. 
Nevertheless, taken together, dynamic cycling and interplay with other PTMs make O-GlcNAc 
ideally suited as a nutrient and stress responsive molecular switch.  
Various noxious stimuli including heat shock, nutrient depletion, ER dysfunction, and 
redox imbalance cause fluctuations in global O-GlcNAc levels to help combat these stressors. 
Aberrant O-GlcNAc cycling has been linked to chronic human diseases, including 
neurodegeneration, cancer, diabetes mellitus, and X-linked intellectual disability (XLID) [2,3]. The 
diverse physiological roles of O-GlcNAc and its emerging importance in human health underscore 
the importance of uncovering the complex molecular mechanisms orchestrating its installation 
and removal on protein targets, both in normal physiology and pathological states. 
Herein, we summarize the biochemical underpinnings of the O-GlcNAc modification and 
integrate salient concepts pertinent to its regulation. Notably, the O-GlcNAc enzymes have 
evolved elaborate multi-domain structures that are ideally suited to enable the integrated fine-
tuning of their function by diverse regulatory mechanisms. Accordingly, we start with an 
overview of their structures and then consolidate select recent literature illuminating key 
regulatory mechanisms that define the abundance, localization, and specificity of the O-GlcNAc 
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cycling enzymes. We focus on emerging interconnected regulatory processes including:  
subcellular localization, PTMs, protein-protein interactions, metabolic control, and 
transcriptional and post-transcriptional regulation (Figure 1). Throughout, we highlight current 
paradigms and raise key unanswered questions. Due to space constraints we regrettably make 
various omissions to focus on the selected literature most relevant to this topic.  
 
 
 
Figure 1. Concept map depicting the interconnected mechanisms regulating target selective O-
GlcNAcylation by OGA and OGT. Each dotted arrow represents higher-level crosstalk between 
the various regulatory mechanisms. 
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OGT structure and polypeptide acceptor specificity  
OGT encodes a metal-independent CAZY (www.cazy.org) family GT41 β-N-
acetylglucosaminyltransferase belonging to the GT-B superfamily of glycosyltransferases. This 
essential gene is located on the X-chromosome and encodes a modular protein composed of five 
distinct regions: i) an N-terminal region consisting of an isoform specific number of contiguous 
helix-turn-helix tetratricopeptide repeats (TPRs), ii) a transitional (H3) helix that sits between the 
N- and C-terminal halves, iii) a C-terminal region containing the GT41 catalytic domain with two 
catalytic lobes (Cat1 and Cat2) that each have a Rossmann fold, iv) an intervening domain with a 
topologically novel fold comprised of a seven stranded β-sheet core stabilized by flanking α-
helices (IntD), and v) a putative C-terminal phosphatidylinositol-binding region (PPO) (Figure 2A). 
There are three different isoforms of OGT expressed in human cells that vary in the number of 
N-terminal TPRs. Nucleocytoplasmic OGT (ncOGT) has 13.5 TPR repeats, mitochondrial OGT 
(mOGT) has 9 repeats, and short OGT (sOGT) has 2.5 repeats (Figure 2A). These isoforms have 
distinct subcellular localization patterns and activities (see localization section below).  
In 2011, the seminal crystallographic structure of human OGT was determined 
illuminating its unique atomic architecture. The structure comprises 4.5 N-terminal TPR repeats 
and the full C-terminal catalytic region in a ternary complex with UDP and a CKII peptide substrate 
(hereafter called hOGT4.5) [4]. The TPRs in this structure (aa 313-400) overlap with an earlier OGT 
crystal structure consisting of 11.5 TPR repeats, and alignment of the two structures provides a 
putative model of the full-length protein (Figure 2B) [4]. The TPR superhelix consists of two layers 
of helices, an inner concave face formed by helix-A and an outer convex face formed by helix-B. 
Notably, helix-A has a highly conserved asparagine ladder that runs the length of the TPR domains 
that is involved in binding to peptide acceptors (see below) [4]. The C-terminal end of the TPR 
superhelix packs against the catalytic domain carving out a narrow acceptor peptide binding 
groove that feeds into the catalytic centre found at the interface of Cat1 and Cat2 [4]. The Int-D 
domain packs against the outer face of the Cat2 lobe oriented away from the active site core. 
The function of the Int-D domain remains unknown but in conjunction with a Cat2 helix, and the 
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C-terminal PPO, it forms a large electropositive surface comprising ten lysine residues that may 
be involved in ligand binding (see below) [4].   
As an inverting glycosyltransferase, OGT catalyzes the formation of a β-glycosidic linkage 
between GlcNAc and the acceptor peptide serine. The peptide acceptor binds OGT 
predominantly through amide backbone hydrogen bonds with the β-hydroxyl group of its 
glycosylated serine projecting directly into the nucleotide sugar binding site. The peptide 
acceptor covers the solvent exposed face of the bound UDP-GlcNAc, effectively trapping it within 
the active site (Figure 3A). This observed binding mode in combination with kinetic data  support 
the broadly accepted proposal that OGT catalyzes glycosyltransfer via an ordered bi-bi 
mechanism whereby UDP-GlcNAc must bind the active site first followed by the acceptor peptide 
[4]. Intriguingly, fundamental mechanistic details remain unknown, including the identity of 
general base responsible for deprotonating the catalytic serine [4]. Briefly as reviewed [4], three 
alternative general bases were proposed including His498, Asp554, or the ü-phosphate of UDP-
GlcNAc. Although mutation of His498 results in inactive enzyme, the side chain interactions 
suggest it is protonated at neutral pH making it poorly suited to serve as a general base. Direct 
デヴ;ﾐゲaWヴ ﾗa ; ヮヴﾗデﾗﾐ デﾗ ü-phosphate of UDP-GlcNAc appears energetically unfavorable. Structural 
studies, however, revealed a series of ordered water molecules in the active site acting as a 
potential proton shuttle adjacent to Asp554 and functional studies reveal defective sugar transfer 
when this residue was mutated to asparagine, offering the best support for the identity of the 
general base to date.  
OGT lacks a strict consensus sequence governing its activity. However, subtle sequence 
preferences help govern substrate selectivity. The specificity of OGT was assessed using a 
saturation library of 3,480 unique acceptor peptides displayed in a monolayer. As predicted by 
earlier work [5], valine and alanine were preferred in the -3 and +2 subsites. Additionally, a 
preference for aromatic residues in the -4 position was uncovered [6]. Notably, proline was 
previously shown to be preferred at the -2 subsite [5]. In contrast, proline at the +1 position has 
been found to prevent O-GlcNAcylation within certain peptides [7]. OGT predominantly 
glycosylates serine and threonine residues located within disordered regions on protein targets 
but also appears able to glycosylate residues positioned in a variety of different secondary 
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structures [8]. However, these secondary structures may need to be unfolded to be 
accommodated within the OGT active site. Although not yet characterized, such local unfolding 
may be triggered in response to various stimuli, or potentially occur during the co-translational 
O-GlcNAcylation of some nascent chains [9], prior to protein folding. The presence of other PTMs 
can also influence protein targeting as exemplified by the observation that acceptor peptide 
phosphorylation can reduce OGT catalyzed O-GlcNAcylation in vitro [7].  However, elucidating 
the physiological significance of this proposed PTM code awaits quantitative analysis of levels on 
endogenous proteins. 
Emerging evidence shows that peptide binding occurs not just in the GT41 active site but 
also within the TPR domains. A protein microarray in conjunction with UDP-GlcNAz was used to 
establish OGT targeting of proteins using downstream click-chemistry to incorporate biotin [10]. 
This method was used to assess the catalytic contribution of a poly-asparagine ladder located 
within the TPR domains, known to engage in numerous bidentate hydrogen bonds with the 
peptide backbone of Tab1 [11] (Figure 3A).  An OGT mutant construct consisting of alanine in 
place of these 5 asparagine residues (5N5A) retained activity toward short peptides but impaired 
modification of proteins [10], supporting the importance of these residues in indiscriminate 
recognition of the polypeptide backbone of proteins distant from the site of glycosylation. In a 
different approach, the Jiang group developed a GlcNAc electrophilic probe (GEP) that consists 
of a UDP-GlcNAc analog containing an allyl chloride electrophile extending as an N-acyl group 
from the 2-amino position [12]. This GEP was used to discern whether mutations in OGT affected 
sugar binding or protein acceptor binding and glycosylation by examining its relative partitioning 
to OGT (C917) or the acceptor protein. This method yielded results further supporting an 
important role for the asparagine ladder in acceptor protein binding [12]. Recently, the XLID OGT 
mutation, L254F, within the seventh TPR was found to distort the TPR superhelix resulting in 
reduced thermal stability and catalytic activity [13]. Furthermore, five additional mutations 
mapping to the OGT TPR domains have recently been correlated with XLID [13-15]. Very recently, 
two aspartate residues (D386 and D420) located in the OGT TPR lumen distal from the active site 
were shown to be important for substrate selection. Interestingly, mutation of these residues to 
alanine altered substrate specificity and increased rates of protein glycosylation in vitro. In 
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particular, a preference was found for substrates with a lysine or arginine positioned 7-11 
residues away from the site of glycosylation [16]. Taken together, the OGT TPR domains are 
emerging as essential mediators of substrate binding, enzyme activity, and stability. 
OGA structure and target specificity  
OGA encodes two distinct splice variants referred to as long (OGA-L) and short (OGA-S) 
isoforms. Human OGA-L (hOGA) consists of three domains connected by disordered regions: i) 
an N-terminal N-acetyl-é-D-glucosaminidase I;デ;ﾉ┞デｷI Sﾗﾏ;ｷﾐ ふCAZ┞  GHΒヴぶ ┘ｷデｴ ; ぷふéっüぶ8] triose-
phosphate isomerase (TIM) barrel structure, ii) a helical bundle referred to as the stalk domain 
composed of four ü-helices, and iii) a C-terminal pseudo histone acetyl-transferase (HAT) domain 
with a GCN5 acetyltransferase-like fold (Figure 2C). The pseudo-HAT domain lacks the conserved 
P-loop motif required for binding of the cofactor, acetyl-CoA, implying that it likely has a non-
enzymatic function. OGA-S lacks the pseudo-HAT domain and part of the stalk domain, leading 
to greatly reduced enzyme activity. 
Recently, three groups independently solved the long-anticipated crystal structure of 
hOGA. This was achieved by the systematic design of various constructs lacking disordered 
regions [17-19]. The homodimer is stabilizWS H┞ ; Sﾗﾏ;ｷﾐ ゲ┘;ヮヮWS ｴWﾉｷ┝ ふüヱΑぎ ;; ヶΑヶ-694) 
[18,19]. Notably, a construct lacking this α17 helix (residues 1-662) does not dimerize and 
displays 100-fold lower catalytic efficiency as compared to WT OGA in processing pNP-GlcNAc 
suggesting that dimerization is required for maximal activity [19]. 
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Figure 2. Domain structure and isoforms of OGT and OGA. A) Schematic of hOGT showing splice variants 
and constructs used for crystallography.  OGT is found as three isoforms distinguished by the number of 
TPRs. The TPRs are shown in yellow, the NLS (D451-P453) is coloured purple, transitional helix (H3) is 
white, the glycosyltransferase catalytic domains are illustrated in light blue and dark blue, the Int-D 
(intervening domain) is red, and the phosphoinositide binding domain of OGT (PPO) is coloured orange 
┘ｷデｴ ゲWケ┌WﾐIW ﾐ┌ﾏHWヴWS ;IIﾗヴSｷﾐｪ デﾗ UﾐｷPヴﾗデKBっS┘ｷゲゲPヴﾗデ ;IIWゲゲｷﾗﾐ ふP56558.1). In panels A and C, 
putative PTMs compiled using PhosphoSitePlus [20] are represented on ncOGT and OGA-L as follows: 
phosphorylation (yellow), O-GlcNAcylation (blue), ubiquitinylation (green), acetylation (red), and 
sumoylation (black). High confidence PTM sites with 5 or more references or experimentally determined 
by low-throughput mass spectrometry mapping methods are shown with solid lines and bold colours. 
Lower confidence sites with fewer than 5 references and determined by high-throughput methods are 
shown with dotted lines and light colours. B) Overall crystallographic model of ncOGT. The model was 
built by superposing hOGT4.5 (PDB ID: 3PE3) and hOGT TPR11.5 (1W3B). High confidence PTMs are labelled, 
as well as domains and key active site catalytic residues. C) Schematic of human OGA splice variants as 
well as constructs used for crystallography. Disordered regions are shown in black, the N-terminal GH84 
domain is illustrated in orange, the helical bundle domain is purple, the C-terminal stalk domain is shown 
in red and the pseudo HAT domain is represented as a green cartoon. The caspase-3 cleavage site is 
indicated by scissors. D) Overall crystallographic model of hOGA. The hOGA Split1 crystal structure (PDB 
ID: 6HKI) is shown attached at the C-terminal end (Y715) to a homology model of the OGA pseudo-HAT 
domain constructed using Phyre2 from the Oceanicola granulosus homolog (PDB ID: 3ZJ0, 29% sequence 
identity). Structures in B and D are colour coded as in A and C with high confidence PTMs labelled on the 
structures.  
 9 
 
A V-shaped active site cleft (~22 x 25 Å with an angle of ~70 °) is formed at the interface of the 
catalytic domain of monomer A and the stalk domain of monomer B [18] (Figure 2D). Multiple 
hOGA-glycopeptide bound structures reveal peptides bind within the cleft in either orientation 
[18,21,22] (Figure 3B-C). Two conserved aspartate residues flank the glycosidic bond, acting as 
ｪWﾐWヴ;ﾉ ;IｷSっH;ゲW I;デ;ﾉ┞ゲデゲ デﾗ a;Iｷﾉｷデ;デW ; デ┘ﾗ-step catalytic mechanism involving a transient 
oxazoline intermediate [4]. Kinetic analysis of OGA mediated O-GlcNAc hydrolysis on intact 
proteins revealed that OGA indiscriminately cleaves diverse O-GlcNAc sites across different 
targets with roughly equivalent catalytic efficiency [23], an observation that is supported by the 
enzyme cleaving O-GlcNAc residues incorporated at unnatural sites [24]. This promiscuous 
substrate selectivity is likely in-part due to the predominant interaction of OGA with amide 
backbone atoms within the bound glycopeptide. As seen elsewhere [23], the rate of OGA 
catalyzed hydrolysis of an O-GlcNAcylated serine was shown to be reduced by half in the 
presence of an adjacent phosphotyrosine on a ZO3-derived model peptide 
(RESSYDIY(p)RVPSS(g)QS) [25]. The ability for PTMs to influence OGA catalyzed removal merits 
further investigation. In summary, recent research has provided a vital structural foundation for 
understanding OGA and OGT. The challenge for the future is to build upon this knowledge to 
uncover how regulatory factors modulate their structure and function to choreograph target 
specific O-GlcNAcylation. 
 
Localization  
The O-GlcNAc cycling enzymes adopt distinct subcellular loci during different phases of 
the cell cycle, in response to stimuli, and across cell types. The OGT and OGA isoforms (Figure 2) 
have long been known to display different subcellular localization patterns; ncOGT is found 
within the nucleus and cytoplasm, sOGT is predominantly localized to the cytosol, and mOGT is 
thought to be largely mitochondrial  though this is a topic of some debate [26,27]. OGA has two 
dominant splice variants with OGA-L being nucleocytosolic with preferential localization in the 
cytoplasm and the largely inactive OGA-S residing in the nucleus and on the surface of nascent 
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lipid droplets, where it is thought to regulate proteasome-mediated droplet remodelling (Figure 
4A) [1].    
 
Figure 3. Active-sites of OGT and OGA. A) OGT in complex with a TAB1 peptide. The bound peptide is 
fused to the N-terminus of OGT and is shown in purple (PDB ID: 5LVV). Asparagine ladder residues shown 
in yellow are highlighted against the yellow TPRs. The peptide covers the solvent exposed face of UDP-
GlcNAc, shown in green, with the active site highlighted. B) Overlay of OGA in complex with various 
ヮWヮデｷSWゲく TｴW aﾗﾉﾉﾗ┘ｷﾐｪ ヮWヮデｷSWゲ ;ヴW Sｷゲヮﾉ;┞WSぎ ü-crystallin B (PDB ID: 5VVV, dark green, residues TSTSL), 
ELK1 (PDB ID: 5VVT, light green, residues TLSP), TAB1 (PDB ID: 5VVU, pink, residues PYSS), Lamin B1 (PDB 
ID: 5VVX, yellow, residues SSRVT), and p53 (PDB ID: 5UN8, purple, residues WVDSTPP). The peptides are 
shown as worms with the N- and C-termini labelled. The catalytic and neighbouring residues are 
highlighted in the active site in orange. C) Superposition of peptide bound OGA complexes. The bound 
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ヮWヮデｷSWゲ ü-crystallin B (PDB ID: 5VVV) and p53 are shown in cyan and purple. Key hydrogen bond 
interactions are coloured according to peptide. 
 
  
Excitingly, the molecular mechanisms regulating these isoform specific localization 
patterns are beginning to emerge. Recently, the ncOGT nuclear localization signal (DFP; residues 
451-453), which is required for interaction with importin α5 and subsequent translocation 
through the nuclear pore complex (NPC) (Figure 4A) was characterized [28]. mOGT is proposed, 
based on sequence analysis, to contain a putative N-terminal mitochondrial targeting sequence. 
Consistent with this hypothesis, OGT appears highly concentrated in the mitochondrial inner 
membrane where it interacts with electron transport chain complex IV and is suspected of O-
GlcNAcylating various mitochondrial proteins [29]. Curiously, the pyrimidine nucleotide carrier 1 
transporter protein (SLC25A33) translocates UDP-GlcNAc from the cytosol to the mitochondrial 
matrix, potentially facilitating mOGT catalyzed mito-specific glycosyltransfer (Figure 4A) [29]. 
Isoform specific siRNA knockdown of mOGT leads to Drp1 dependant mitochondrial 
fragmentation, reduced membrane potential, and loss of mitochondrial content, supporting an 
important role for OGT in maintaining mitochondrial integrity and function [27].  
 In addition to these isoform specific localization patterns, overexpression of tagged O-
GlcNAc cycling enzymes shows their partitioning to distinct subcellular locations during cell 
division and in response to signalling events. During mitosis, OGT is concentrated at the central 
spindle assembly during anaphase, and the midbody during cytokinesis. This is consistent with 
the formation of transient complex between OGT, OGA, mitotic Aurora kinase B (AURKB), and 
protein phosphatase 1 (PP1), which regulates vimentin filament glycosylation to control 
intermediate bridge formation and severing during cytokinesis (Figure 4B) [30]. Recently, 
localization of endogenously expressed O-GlcNAc cycling enzymes as well as global O-
GlcNAcylation were investigated in bovine and human oocytes during meiosis by 
immunocytochemistry and confocal microscopy [31]. O-GlcNAcylated proteins were distributed 
throughout the nucleus and cytoplasm with enrichment at the nuclear envelope during 
prophase-I, whereas during metaphase O-GlcNAcylated substrates localized throughout the 
cytoplasm with slight enrichment at the cortex. OGA was localized at the cortex throughout 
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meiosis, whereas OGT was localized to the meiotic spindles [31]. These results support the idea 
that localization of the O-GlcNAc cycling enzymes is regulated during cell division. Despite having 
cell division-dependent localization patterns the mitotic and meiotic roles of the O-GlcNAc cycling 
enzymes remain poorly understood, though altering levels of these enzymes clearly affects cell 
division. Upon prolonged insulin stimulation of 3T3-L1 adipocytes, a subset of ncOGT is proposed 
to be recruited to the plasma membrane by phosphatidylinositol (3,4,5)-triphosphate (PIP3), to 
modulate the insulin signalling pathway by O-GlcNAcylation (Figure 4A) [32-34]. OGT was initially 
proposed to have a PIP3 binding site located in the C-terminal catalytic and Int-D domains, 
however, this topic remains controversial [4]. We speculate that this type of triggered localization 
of the O-GlcNAc cycling enzymes may be relatively common to enable temporal control of O-
GlcNAc levels at distinct subcellular locations. Yet, the molecular bases for these changes need 
more focused biochemical studies combined with cell-based experiments. 
Finally, OGT displays cell type specific localization patterns. For example, OGT is enriched 
in the postsynaptic density of excitatory synapses perhaps to enhance the O-GlcNAcylation of 
multiple proteins as seen to occur upon neuronal stimulation. Postsynaptic KO of OGT decreases 
synaptic expression of ionotropic transmembrane glutamate receptor AMPA subunits (GluA2 and 
GluA3), reduces presynaptic terminals, and stunts the development of mature dendritic spines 
[35]. Future discovery-based investigations to systematically catalogue OGA and OGT localization 
patters across diverse cell types and in response to varied stimuli would likely be illuminating, as 
has been the case for kinases and phosphatases.  
 
Post-translational modifications  
The O-GlcNAc enzymes are decorated with numerous PTMs. In fact, a survey of the 
PhosphoSitePlus database reveals that proteomic discovery-based mass spectrometry efforts 
have uncovered a total of 55 and 42 distinct PTMs on human OGT and OGA (Figure 2) [20]. For 
OGT, a handful of these PTMs have been ascribed functions including dynamic fine-tuning of its 
localization, turnover, and substrate specificity (Table 1). O-GlcNAcylation of OGT Ser389 within 
TPR12 enables its nuclear localization [28]. Similarly, AMPK mediated phosphorylation of Thr444 
contributes to OGT nuclear import in myotubes [36]. We note that the T444 and S389 
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phosphosites are both located within TPR12 in proximity to the recently characterized NLS (451-
453), and thus may regulate recruitment of the nuclear import machinery. This NLS is present in 
all OGT isoforms, however, its contribution to nuclear import has only been investigated in 
ncOGT. Phosphorylation of OGT T444 changes its substrate selectivity in vitro and in proliferating 
HEK293T kidney cells, and alters its binding partners. T444 phosphorylation thus appears to 
regulate OGT target specificity, localization, and protein-protein interactions  phenomena that 
are likely not mutually exclusive. Upon glucagon-ｷﾐS┌IWS I;ﾉIｷ┌ﾏ ゲｷｪﾐ;ﾉｷﾐｪが I;ﾉIｷ┌ﾏっI;ﾉﾏﾗS┌ﾉｷﾐ-
dependant kinase II (CamKII) phosphorylates OGT S20, which alters the specificity of OGT to 
promote O-GlcNAcylation and activation of the Ulk proteins involved in autophagic induction 
[37]. Similarly, Checkpoint kinase 1 (Chk1) also phosphorylates Ser-20, and this event was 
separately found to stabilize OGT against proteasomal degradation and be required for its 
previously mentioned localization to the midbody upon cytokinesis (Figure 4B) [38]. 
Understanding the roles of OGT phosphorylation may yield insight into its stimulus-induced 
spatiotemporal regulation. Even less explored are the multiple putative ubiquitinylation sites 
discovered on OGT in proteome-wide mass spectrometry experiments (PhosphoSitePlus 
database [20]). For example, the LSD2 histone demethylase acts as an E3 ligase and targets OGT 
for polyubiquitinylation at an unknown site, thereby promoting its proteasomal degradation [39], 
whereas the BAP1 deubiquitinase protects OGT against UPS mediated degradation [40]. 
However, the identities of the E1 and E2 enzymes regulating these UPS mediated degradation 
pathways remain unknown.  
PTMs can also directly modulate OGT catalyzed glycosyltransfer. OGT can be 
phosphorylated at S3 and S4 by glycogen synthase kinase 3β (GSK3β) [41]. Interestingly, GlcNAc 
has also been identified on OGT S3 and S4 suggesting the possibility that O-GlcNAcylation and 
phosphorylation may antagonize each other at this site [41]. Although an appealing hypothesis, 
O-GlcNAc and phosphorylation are both most often substoichiometric and, accordingly, such 
proposed direct reciprocal crosstalk has been difficult to clearly demonstrate as this would 
require quantitative assessment of PTMs on endogenous proteins. Taken together, the roles for 
PTMs in controlling OGT localization, turnover, and activity are slowly emerging. The challenge 
for the future is to confirm these effects, decode the combinatorial influence of these diverse 
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PTMs on OGT function in response to subcellular signalling, and delve deeper into the structural 
and biochemical basis behind these observations.  
OGA is also heavily decorated with PTMs, however very little is understood regarding 
their functional ramifications. During apoptosis, OGA is cleaved by caspase-3 within a non-
canonical S410VVD413 recognition site [42]. Co-expression of the two caspase-3 cleavage products 
recapitulates OGA activity in cells, suggesting the two halves remain associated within cells. 
However, a functional role for this cleavage has not been defined. Studies have reproducibly 
identified GlcNAc at S405, yet it is not known whether this modification has a functional role [20]. 
Bearing in mind that individual sites of modification do not necessarily have physiological roles, 
identifying those which do and exploring how some of these post-translational events influence 
OGA function will bridge a key gap in our understanding of the regulation of O-GlcNAc.  
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Figure 4:  Modulation of OGA and OGT localization by PTMs and protein binding partners. A) 
Subcellular localization of OGA and OGT. Importin α5 facilitates the nuclear import of ncOGT and 
this process is dependent upon S389 O-GlcNAcylation and AMPK mediated T444 
phosphorylation. The OGT-S isoform is predominantly cytosolic. OGA-L localizes to the cytosol 
and nucleus, and OGA-S exists in the nucleus and on the surface of lipid droplets. OGA-L and 
mOGT localize to the mitochondria, and mOGT associates with complex IV. B) OGT and OGA 
localization and complexation during mitosis. OGT is localized almost exclusively to the midbody 
during mitosis. In contrast, OGA localizes diffusely throughout the cell. OGT, OGA, AURKB, and 
PP1 are thought to form a complex at the midbody during mitosis. This complex modulates 
vimentin intermediate filament formation and disassembly, thereby regulating segregation of 
daughter cells during cytokinesis. We note that structural details regarding the (OGT, OGA, 
AURKB, PP1) complex remain unresolved, therefore, our representation of this complex in panel 
B is for illustrative purposes only. 
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Interaction partners 
Interaction partners play an integral role in modulating the activity and localization of the 
O-GlcNAc cycling enzymes. Here, we focus on select recent examples germane to the regulation 
of O-GlcNAc. The nuclear receptor REV-ERBα integrates the circadian clock with both glucose and 
lipid metabolism and has recently been shown to interact with and modulate OGT [43].  REV-
ERBα shields cytoplasmic OGT from proteasomal degradation and appears to enhance OGT 
catalytic activity in the nucleus, thereby increasing O-GlcNAcylation of proteins within both 
compartments. For example, REV-ERBα is proposed to promote OGT-mediated regulation of 
insulin signalling by boosting O-GlcNAcylation of AKT in the cytoplasm [43]. Thus, REV-ERBα 
exerts pleiotropic circadian activities through direct interaction with OGT. 
UDP-N-acetylglucosamine pyrophosphorylase-1 (UAP1) catalyzes the last step in the 
synthesis of UDP-GlcNAc. A UAP1 paralog, UAP1-like-1 (UAP1L1), is required for OGT mediated 
protein O-GlcNAcylation in HepG2 liver hepatocellular carcinoma cells [44].  Surprisingly, UAP1L1 
does not efficiently catalyze UDP-GlcNAc synthesis, but instead interacts directly with the C-
terminal catalytic domain of OGT. Knockdown of UAP1L1 markedly reduced global O-
GlcNAcylation in HepG2 and TONG cells, yet UAP1L1 alone is not sufficient to bolster OGT activity 
in vitro [44]. Thus, UAP1L1 likely maintains OGT activity within cells through direct binding, 
though more detailed characterization is necessary.  
5-methylcytosine (5mC) in DNA plays important roles in transcriptional regulation, 
genomic imprinting, and suppression of transposable elements. The TET1-3 (Ten Eleven 
Translocation) proteins oxidize 5mC and thereby facilitate reversal of locus specific DNA 
methylation particularly within promoter regions [45]. Though sometimes contradictory, a range 
of studies have shown OGT binds to TET proteins and regulates their activity (reviewed in, [46]). 
Sadly, aside from the work on REV-ERBα [43], this promising area has largely languished since 
2015 and a challenge for the future is to better determine the context-dependant effects of these 
interactions on chromatin structure and gene regulation. 
To identify putative OGA binding partners, BioID proximity biotinylation in combination 
with stable isotope labeling of amino acids in cell culture (SILAC) was used [47]. This analysis 
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revealed 90 proteins displaying stress-dependant interactions with OGA. OGA interactions with 
fatty acid synthase (FAS), filamin-A, heat shock cognate 70 kDA, and OGT were verified by co-
immunoprecipitation. In vitro analysis of the pool of OGA bound to FAS revealed it had only ~15%  
of the activity of free enzyme, and FAS overexpression appeared to boost oxidative stress-
induced global O-GlcNAc levels in cells [47]. Overall, the structural and biochemical features 
governing these protein-protein interactions remain unexplored and limit our understanding of 
how binding partners functionally regulate OGT and OGA. 
 
 
Table 1 
Key post-translational modifications and processing events on OGT and OGA  
Protein (residue) Modification Functional role Enzyme(s) Ref. 
OGT (S3) Phosphorylation, O-GlcNAc Increases activity GSK3β [41] 
OGT (S4) Phosphorylation, O-GlcNAc Increases activity GSK3β [41] 
OGT (S20) Phosphorylation OGT ;Iデｷ┗ｷデ┞ っ ﾏｷデﾗデｷI ﾉﾗI;ﾉｷ┣;デｷﾗﾐ Chk1, CamKII [37,38] 
OGT (S389) O-GlcNAc Required for nuclear localization OGT [28] 
OGT (T444) Phosphorylation Nuclear uptake and activity AMPK [36] 
OGT (D451-P453) Nuclear localization signal Nuclear uptake  *N.A. [28] 
ΨOGT (Y989) Phosphorylation Increased activity IR, Src [32] 
OGA (S364) Phosphorylation Unknown Unknown [20] 
OGA (S405) O-GlcNAc Unknown Unknown [20] 
OGA (S410-D413) Proteolysis site Unknown Caspase-3 [42] 
*N.A. means non-applicable 
Ψ Speculative modification proposed based on blots and sequence analysis on rat OGT Y979 (hOGT Y989) 
 
Metabolic Regulation 
The concentration of the UDP-GlcNAc donor substrate used for OGT catalyzed 
glycosyltransfer is responsive to nutrient flux due to the direct dependency of HBSP on major 
cellular metabolites. In particular, intracellular concentrations of glucose, glutamine, fatty acids, 
and GlcNAc modulate HBSP flux and UDP-GlcNAc abundance (for an early perspective see [48]). 
Notably, HBSP enzyme expression and allosteric modulation are under tight control and respond 
to various changes in nutrient and metabolite abundance and intracellular signalling (reviewed 
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in [49]). For example, the unfolded protein response (UPR) signal transducer, spliced X box-
binding protein 1 (XBP1), acts as a transcriptional activator to induce expression of rate-limiting 
HBSP enzymes boosting cellular O-GlcNAcylation in response to ER stress [50]. While nutrient 
supply clearly alters UDP-GlcNAc levels, nutrient flux may also induce intracellular signalling 
pathways that ultimately modulate the abundance and function of the O-GlcNAc cycling 
enzymes. Accordingly, while generally accepted in the field, the effects of nutrients on regulation 
of O-GlcNAc have surprisingly not been systematically investigated to simultaneously monitor 
UDP-GlcNAc levels, levels of HBSP enzymes, OGA and OGT, and downstream levels of O-GlcNAc. 
Such studies would help provide a solid foundation to systematically assess the functional and 
mechanistic basis for the effects of nutrients.   
 
Transcriptional activation and repression 
New findings are emerging to support expression of OGA and OGT being coordinately 
regulated by control of transcriptional programs that work to maintain balanced O-GlcNAc levels. 
For example, increases in OGT lead to concomitant increases in OGA expression, and vice versa, 
in what appears to be an effort to buffer the cell from rapid changes in O-GlcNAcylation. 
Furthermore, treatment of cells with the selective OGA inhibitor ThiametG, boosts O-GlcNAc 
levels and induces a compensatory increase in OGA gene expression and a correlated decrease 
in OGT abundance [51], and the converse is also true for OGT inhibitors [52].  
We are just beginning to uncover transcriptional programs governing these coordinated 
shifts in expression of OGT and OGA. For example, OGA serves as a co-activator in conjunction 
with the histone acetyltransferase p300 to positively regulate transcription factor 
CCAATっWﾐｴ;ﾐIWヴ-HｷﾐSｷﾐｪ ヮヴﾗデWｷﾐ HWデ; ふCっEBPβ)  among the most common activators occupying 
the OGT promoter (Figure 5) [53]. This transcriptional regulatory mechanism enables OGT 
expression to be tuned to OGA levels to balance O-GlcNAcylation. Additionally, the OGA 
promoter is sensitive to OGT expression as exemplified by a recent analysis of O-GlcNAcylation 
in XLID patients. An XLID variant L254F-OGT, results in reduced L254F-OGT protein levels in 
isolated patient lymphoblastoid cells [3]. However, global O-GlcNAc abundance appeared 
unaltered, presumably due to a compensatory decrease in OGA mRNA and downstream OGA 
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levels. OGT appears to be involved in a balancing mechanism that regulates global O-GlcNAc 
levels in XLID through formation of an OGT-mSin3A-HDAC1 repressive complex at the OGA 
proximal promoter region (Figure 5) [3]. Curiously, E2F transcription factor 1 (E2F1) concurrently 
represses transcription at both ogt and oga promoters in a retinoblastoma (Rb1)-dependant 
manner in mice to maintain a balanced mRNA pool (Figure 5) [54].  OGT transcription also appears 
to be regulated by hepatocyte nuclear factor 1 homologue A (HNF1A), which is itself O-GlcNAc 
modified. Loss of O-GlcNAc appeared to increase transcription of OGT, suggesting a mechanism 
for autoregulation of O-GlcNAc homeostasis [55]. Overall, a higher order network of multiple 
transcriptional mechanisms likely act in concert to maintain O-GlcNAc homeostasis but decoding 
this will require both more detailed biochemical and system wide studies. 
Transcription of O-GlcNAc cycling enzymes is also dysregulated in response to other 
specific stimuli. For example, OGT levels are markedly increased in human papillomavirus (HPV) 
induced cervical neoplasms, and transfection of HPV oncogenes into mouse embryonic 
fibroblasts induces a pronounced increase in OGT mRNA and protein levels [56]. HPV infection 
alters the expression of several transcription factors with predicted binding sites within the OGT 
promoter. Overexpression of transcription factors AP-1, SP-1, NF-κB, p65, and c-MYC enhanced 
OGT promoter activity on a reporter construct [56]. However, further in vivo analysis of the 
relative contribution of these transcription factors to enhancement of endogenous OGT 
expression is required. As an additional example, upon lipopolysaccharide stimulation, E2-related 
factor  2 (Nrf2) binds the ogt promoter and enhances its transcription in bone-marrow derived 
mouse macrophages, resulting in amplified O-GlcNAcylation and inhibition of pro-inflammatory 
transcription factor STAT3. Interestingly, Nrf2 is not required for baseline OGT expression but 
rather only boosts its abundance in response to stimuli. Furthermore, the E3 ubiquitin ligase CUL3 
negatively regulates OGT expression through its targeted degradation of Nrf2 (Figure 5) [57]. 
Future efforts should aim to uncover additional cis- and trans-acting factors controlling 
transcription of OGT and OGA and illuminate how they are integrated to tailor transcriptional 
programs in response to various stimuli.  
 
Post-transcriptional regulation 
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MicroRNAs (miRNAs) are short non-coding RNAs that typically hybridize to the 3UTR of targeted 
transcripts. This binding guides Argonaute proteins to direct targeted mRNAs to the miRNA-
ｷﾐS┌IWS ゲｷﾉWﾐIｷﾐｪ IﾗﾏヮﾉW┝ ふﾏｷRISCぶが ﾉW;Sｷﾐｪ デﾗ デヴ;ﾐゲﾉ;デｷﾗﾐ;ﾉ ヴWヮヴWゲゲｷﾗﾐ ;ﾐSっﾗヴ ﾐ┌IﾉWﾗﾉ┞デｷI 
degradation. An early report showed MicroRNA-539 destabilizes OGA mRNA transcripts [58]. 
Recently, miRNA-15b has been shown to target OGT mRNA in Th17 cells [59], and the oxidative 
 
Figure 5. Transcriptional and posttranscriptional regulation of OGA and OGT expression. OGT 
ｷゲ ヴWｪ┌ﾉ;デWS ;デ デｴW デヴ;ﾐゲIヴｷヮデｷﾗﾐ;ﾉ ﾉW┗Wﾉ H┞ ;Iデｷ┗;デﾗヴゲ ふCっEBPβ, Nrf2) that are themselves 
modulated by secondary regulatory mechanisms. Both OGA and OGT promoters are negatively 
regulated by E2F1 in a Rb1 dependant fashion. Furthermore, OGA is thought to be 
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transcriptionally repressed by the OGT-mSin3A-HDAC1 complex. The OGT mRNA transcript 
contains a retained fourth intron with an O-GlcNAc sensitive internal splicing silencer (ISS). In 
conditions of high O-GlcNAc the ISS prevents splicing of the detained intron leading to nuclear 
degradation of the transcript, whereas low O-GlcNAc results in splicing of the intron and 
subsequent nuclear export. The cytoplasmically-localized mature OGT and OGA mRNA 
transcripts are either translated into protein product or can be targeted for degradation via 
hybridization to miRNAs and subsequent RNA-induced silencing. OGT and EZH2 take part in a 
negative feedback mechanism to repress the miRNA-101 promoter. 
 
stress responsive miRNA-200a and miRNA-200b antagonize the OGT mRNA transcript in 
conditions of high glucose in human aortic endothelial cells [59,60]. Recently, miRNA-101 has 
been found to target the transcripts of both OGT and EZH2 for degradation. Interestingly, OGT 
mediated O-GlcNAcylation has been proposed to stabilize EZH2 thereby promoting EZH2 
catalyzed histone H3K27 trimethylation within the miRNA-101 promoter. Because the H3K27me3 
mark transcriptionally silences miRNA-101, a negative feedback mechanism that promotes 
metastatic colorectal cancer may operate (Figure 5) [61]. Finally, in hepatocytes, new data shows 
HCV infection induces miRNA-501-61p binding to the 3UTR of OGT transcripts, blocking 
translation and leading to decreased OGT levels [62]. Moreover, this last observation is 
recapitulated bi-directionally using OGA and OGT inhibitors. On balance, miRNA mediated 
degradation is emerging as a key mechanism regulating context dependant fine control of 
expression of O-GlcNAc cycling enzymes. 
Another post-transcriptional mechanism controlling OGT expression is the regulated 
splicing of its fourth intron, through the recently recognized phenomenon of retained introns (RI) 
[63]. High cellular O-GlcNAc levels are correlated with increased abundance of the RI spliceoform 
of the OGT transcript (OGT-RI) within the nucleus. Notably, pharmacological inhibition of OGT 
reduced OGT-RI levels, which correlated with enhanced OGT expression [63]. Furthermore, a 
526-nts O-GlcNAc sensitive intronic splicing silencer (ISS) located within the fourth intron 
regulates abundance of this non-translated spliceoform (Figure 5) [63]. Currently, the cellular fate 
of the OGT-RI, and the trans-acting factors that bind and regulate the ISS in response to 
fluctuating O-GlcNAc levels represent major unknowns of high interest. 
 
Conclusion  
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In summary, recent crystallographic investigations of OGT and OGA have provided a structural 
foundation for understanding the molecular mechanisms regulating O-GlcNAc cycling. Upon 
exploring the current state of knowledge about these mechanisms, we emerge with a view that 
an interconnected network of regulatory factors dynamically tailors the abundance, localization, 
and activity of the O-GlcNAc cycling enzymes. For example, PTMs and protein interaction 
partners can exert pleiotropic effects on the localization and activity of OGT and OGA (Figure 5). 
Pre-translational regulatory mechanisms are emerging as major factors orchestrating global O-
GlcNAc homeostasis. Additionally, nutrient-based regulation plays defined roles as well, both 
through modulation of these processes and by directly regulating levels of donor sugar 
substrates. While many new regulatory processes are emerging, understanding of events at the 
atomic level remains largely unknown. A major challenge is to integrate cell and tissue-based 
discovery studies with quantitative biochemical analyses to uncover the detailed molecular and 
atomic basis for regulation of O-GlcNAc. Such findings will illuminate how these events are 
antagonistic or synergistic in coordinating both global and target specific O-GlcNAcylation to 
meet cellular needs. Finally, given that O-GlcNAc is emerging as a druggable pathway, delving 
deeper to uncover these mysteries will likely enable targeted therapeutic approaches that 
modulate O-GlcNAc for human benefit.  
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References and recommended reading 
Papers of particular interest, published within the period of review, have been highlighted as: 
*of special interest 
** of outstanding interest 
 
**[3] An important paper in the field. The authors provide unambiguous evidence for mutations 
in ogt implicated in XLID influencing OGT function. Despite largely normal global O-
GlcNAc levels, significant changes in gene transcription are observed. Furthermore, a 
compensatory mechanism to maintain global O-GlcNAc levels involving OGT-mSin3A-
HDAC1 dependant transcriptional repression at the OGA promoter is proposed. 
*[6] The authors develop a systematic platform for glycosylation sequence characterization and 
optimization and use this method to characterize OGT sequence preference. This 
analysis revealed a surprising preference for an aromatic residue at the -4 subsite. 
*[10] An asparagine ladder in the TPR domains mediates OGT interaction with protein substrates. 
* [12] New chemical biology tools to identify features of OGT responsible for substrate targeting. 
This method uncovered a patch of residues lining the inner surface of the N-terminal 
domain that contribute to interaction with multiple substrates.  
**[13] A nice structural study defines the effect of XLID-associated OGT mutation L254F as 
distorting the TPR helix.  
* [27] mOGT was shown to be catalytically active in vivo and plays an important role in supporting 
mitochondrial structure and function. 
**[28] A fundamental advance in discovery of the OGT NLS and the effects of S389 O-
GlcNAcylation and interaction with importin α5 for nuclear import. 
*[35] The authors demonstrate that OGT is enriched in the post-synaptic density of excitatory 
neuronal synapses whereby it regulates synapse maturation.  
*[37] Upon glucagon-induced calcium signalling CamKII phosphorylates OGT at S20, which 
induces O-GlcNAc modification of Ulk proteins through potentiation of AMPK-
dependant phosphorylation. 
**[38] Chk1 phosphorylates OGT S20, and this modification regulates OGT localization to the 
mid-body and regulation of vimentin bridge formation and severing during mitosis. 
*[39] LSD2 was shown to act as an E3 ligase to ubiquitinylate OGT and thereby facilitate its UPS 
mediated degradation. 
**[43] Circadian nuclear receptor REV-ERBα was found to form a stable complex with OGT and 
regulate OGT-controlled processes in both the cytosol and nucleus. 
*[44]  The authors characterize UAP1L1 as a novel OGT binding partner that is necessary for O-
GlcNAcylation in cells.  
**[47] This study leverages BioID proximity biotinylation to identify 90 OGA-interaction partners 
including FAS, which when bound causes a substantial reduction in OGA catalytic 
activity.  
** [52] The authors report the structure based evolution of OGT inhibitors with nanomolar 
affinity. Moving forward, these inhibitors may provide a key tool to facilitate discovery 
and targeted studies of O-GlcNAc in cells.  
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*[53] This study demonstrates that OGA acts in conjunction with histone acetyltransferase p300 
to ヮﾗゲｷデｷ┗Wﾉ┞ ヴWｪ┌ﾉ;デW デヴ;ﾐゲIヴｷヮデｷﾗﾐ a;Iデﾗヴ CっEBPβ, which acts as a transcriptional 
activator at the ogt promoter. 
* [57] Nrf2 was demonstrated to bind the ogt promoter and enhance transcription. Furthermore, 
E3 ubiquitin ligase CUL3 negatively regulates ogt transcript through targeted 
degradation of Nrf2. 
* [61] The authors demonstrate that miRNA-101 targets degradation of both OGT and EZH2. 
Furthermore, OGT and EZH2 catalyze O-GlcNAcylation and H3K27 trimethylation within 
the miR-101 promoter providing a negative feedback mechanism that transcriptionally 
silences miRNA-101. 
**[63] An exceptional finding. Retention of the OGT fourth intron is sensitive to global O-GlcNAc 
levels. Furthermore, this retained intron contains an ISS that regulates its splicing  by 
what mechanism remains a tantalizing mystery. 
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